Press release
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) Pipeline Research Report, H1, 2017
Market Research Hub
Request Free Sample Report @ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1177482
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Iduronate 2-sulfatase (IDS) is a sulfatase enzyme associated with Hunter syndrome. Iduronate 2-sulfatase is required for the lysosomal degradation of heparan sulfate and dermatan sulfate. Mutations in this X-chromosome gene that result in enzymatic deficiency lead to Hunter syndrome. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 4, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Genetic Disorders and Central Nervous System which include indications Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) and Cognitive Impairment.
Furthermore, this report also reviews key players involved in Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Scope
- The report provides a snapshot of the global therapeutic landscape for Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13)
- The report reviews Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics and enlists all their major and minor projects
- The report assesses Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics
Browse Full Report with TOC @ http://www.marketresearchhub.com/report/iduronate-2-sulfatase-alpha-l-iduronate-sulfate-sulfatase-or-idursulfase-or-ids-or-ec-31613-pipeline-review-h1-2017-report.html
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Content:
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Overview
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Therapeutics Assessment
Make an Enquiry @ http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1177482
About Market Research Hub:
Market Research Hub (MRH) is a next-generation reseller of Research Reports and analysis. MRH’s expansive collection of chemicals market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
Contact Details:
90 State Street,
Albany, NY 12207,
United States
Toll Free: 866-997-4948 (US-Canada)
Tel: +1-518-621-2074
Email: press@marketresearchhub.com
Read More Industry News @ https://www.industrynewsanalysis.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) Pipeline Research Report, H1, 2017 here
News-ID: 594236 • Views: …
More Releases from Market Research Provider - MRH
Global Sports Accessories Market Status & Growth Analysis Forecasted till 2022
Market Research Hub (MRH) has included a new report titled “Global Sports Accessories Market Research Report 2017”, to its huge database. This research study includes information about the regional production along with revenue and market share. The report further updates that the sports market on the global level would acquire a rise at a positive CAGR during the period 2017-2022, which is surely a major boost for the concerned sector.…
Global Film Release Liners Market to Rise at an Impressive Rate during the Forec …
The demand for film release liners is greatly influenced by the advancements in the packaging industry. The increased preference for modern and latest packaging all across the world, coupled with the increasing investments in the pharmaceuticals and the food and beverages industries, is expected to drive the demand in the global market for film release liners over the coming years. A new market report with a title “Global Film Release…
Global Coated Graphite Market Status, Trends & Future Outlook until 2022
The latest research report added to the vast database of Market Research Hub (MRH). The study is titled “Global Coated Graphite Market Research Report 2017”, which includes information about the regional segmentation on the basis of factors such as production, consumption, revenue, and market share. It is also mentioned that the market would soon acquire growth at a double-digit CAGR between 2017 and 2022.
Request Free Sample Report @ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1217172
Geographically, this…
More Releases for Iduronate
Hunter Syndrome Therapeutics Market Growth, Trends, Industry Analysis and Foreca …
The hunter syndrome therapeutics market is anticipated to grow at a significant CAGR of 5.3% during the forecast period (2022-2028). Hunter syndrome, commonly known as mucopolysaccharidosis II or MPS II, is a rare condition caused by a lack of the lysosomal enzyme iduronate-2-sulfatase. The two primary methods for treatment of symptomatic relief and controlling problems associated with this condition include enzyme replacement therapy (ERT) and hematopoietic stem cell transplant (HSCT).…
Hunter’s Syndrome Market 2021 Statistical Analysis, Key Segments, Benefits and …
Hunter’s syndrome mucopolysaccharidosis type II (MPS II) is a rare genetic disorder in which large sugar molecules called glycosaminoglycans (GAGs) or mucopolysaccharides are produced in body tissues. It is observed to be a form of lysosomal storage disease. Hunter’s syndrome is caused by the deficiency of lysosomal enzyme iduronate-2-sulfatase (I2S). The lack of this enzyme causes heparan sulfate and dermatan sulfate to accumulate in all body tissues. Hunter’s syndrome is…
Hunter Syndrome Pipeline Insight Market Research Report 2020 | Shire, Regenxbio, …
Hunter Syndrome Pipeline Insight, 2020, report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Hunter Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Hunter Syndrome Understanding
Hunter Syndrome: Overview
Mucopolysaccharidosis type II (MPS II),…
Global Iduronate 2 Sulfatase Market, Size, Industry Player (ArmaGen, Bioasis Tec …
Market Research Hub (MRH) has actively included a new research study titled “Global Iduronate 2 Sulfatase Market Size, Status and Forecast 2018-2025” to its wide online repository. The concerned market is discoursed based on a variety of market influential factors such as drivers, opportunities and restraints. This study tends to inform the readers about the current as well as future market scenarios extending up to the period until 2025. In…
Hunter Syndrome Treatment Market Foresees Skyrocketing Growth in the Coming Year …
Hunter syndrome also called as Mucopolysaccaridosis type II (MPS II), is the disorder affecting several parts of the body. Hunter syndrome is inherited genetic disorder caused by a malfunctioning or missing enzyme. At birth hunter syndrome individuals do not display any features of the disorder, amid ages 2 and 4, changes starts to show as large round cheeks, an enlarged tongue, full lips, and a broad nose. As the disorder…
Mucopolysaccharidosis II (MPS II)/ Hunter Syndrome Market Outlook and Forecast u …
Mucopolysaccharidosis II (MPS II)/ Hunter syndrome is a congenital condition which leads to complications in carbohydrate metabolism. The first individual with X-linked Mucopolysaccharidosis (MPS) was first reported in 1917 by a clinician named Hunter. Hunter syndrome is known to occur almost exclusively in males and is characterized by distinctive facial features such as puffy lips, a large head, large rounded cheeks, a broad nose, and an enlarged tongue (macroglossia). Mucopolysaccharidosis…
